Announcements Trials
Browse Landscape

Status

Completed 21Terminated 2Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Observational 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Papillomavirus Infections 1Neoplastic Cells, Circulating 1Abortion, Spontaneous 1

Interventions

pembrolizumab 183Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 53fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 39Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Data Collection × Clear all
NCT05437679 2023-09-05

CHARTER

Angle plc

Terminated
9 enrolled
Genitourinary

Neoplastic Cells, Circulating, Prostatic Neoplasms

NCT01290393 2018-07-26

Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada

GlaxoSmithKline

Terminated
2 enrolled

Abortion, Spontaneous, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡